SCHEMBL24473940

SCHEMBL24473940

CC(C)CCC[C@@H](C)C1CCC2C3CC=C4C[C@@H](OC(=O)CSCC(N)C(N)=O)CC[C@]4(C)C3CC[C@@]21C

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP46A1 Q9Y6A2 2/20 0.68
▸ POLA1 P09884 1/20 0.65
▸ OSBP P22059 3/20 0.59
▸ USP2 O75604 2/20 0.59
▸ RORC P51449 2/20 0.59
▸ LMNA P02545 1/20 0.59
▸ ABCB1 P08183 1/20 0.59
▸ OSBP2 Q969R2 1/20 0.59
▸ NR1H3 Q13133 3/20 0.57
▸ PLA2G2A P14555 1/20 0.54
▸ NPC1L1 Q9UHC9 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ GBA1 P04062 2/20 0.52
▸ UGCG Q16739 2/20 0.52
▸ GBA2 Q9HCG7 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ GRIN1 Q05586 1/20 0.51
▸ GRIN2A Q12879 1/20 0.51
▸ FGF2 P09038 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19578615 1.00 CYP46A1 (0.68) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL16476474 0.93 CYP46A1 (0.67) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL19566728 0.93 CYP46A1 (0.67) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL16104245 0.91 CYP46A1 (0.64) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL25747241 0.91 CYP46A1 (0.63) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL10237705 0.91 CYP46A1 (0.63) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL14964148 0.90 CYP46A1 (0.70) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL24917535 0.90 POLA1 (0.69) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL25797981 0.90 CYP46A1 (0.62) CYP46A1POLA1OSBPUSP2RORC
SCHEMBL16087280 0.89 CYP46A1 (0.57) CYP46A1POLA1OSBPUSP2RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11872261-B2 Lipoprotein targeting protease inhibitors and uses THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-01-16 — — US disclosed
US-20220168379-A1 LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2022-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872261-B2 Lipoprotein targeting protease inhibitors and uses SERPINB1, APOB, APOL1 CYP46A1 291/4885POLA1 1565/4885OSBP 1430/4885
US-20220168379-A1 LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES SERPINB1, APOB, APOL1 CYP46A1 291/4885POLA1 1565/4885OSBP 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback